• Jason Hawthorne
• 28 Feb, 2021

Cases of, hospitalizations for, and deaths attributable to COVID-19 are finally dropping significantly. That's fantastic news for society at large, but it means the makers of coronavirus tests are going to see the eye-popping growth rates they put up in 2020 turn negative. Many are already experiencing steep declines in their stock prices. But at least one of those companies, Fulgent Genetics (NASDAQ:FLGT), promises plenty of growth even in a world without COVID-19. That could make
Read more...